Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Daniel Dauzonne has a total of 7 co-authors. Here are the top co-authors by number of shared publications:

  • Brigitte Bauvois

    Centre de Recherche des Cordeliers, Sorbonne Université, Université Paris Cité, Inserm UMRS 1138, Drug Resistance in Hematological Malignancies Team, 75006 Paris, France

    1 shared publication
  • Faten Merhi

    Research Laboratory of Microbiology (RLM), Department of Life and Earth Sciences, Faculty of Sciences I, Lebanese University, Hadat Campus, P.O. Box 6573/14 Beirut, Lebanon

    1 shared publication
  • Fathi Moussa

    Institut de Chimie Physique, CNRS UMR 8000, Université Paris Saclay, 91405 Orsay, France

    1 shared publication
  • Marie-Joelle Virolle

    Group MES (Métabolisme Energétique des Streptomyces), Institut de Biologie Intégrative de la Cellule (I2BC, UMR 9198), Commissariat à l’Energie Atomique et aux Energies Alternatives (CEA, CNRS), Université Paris-Saclay, 1 Avenue de la Terrasse, 91190 Gif-sur-Yvette, France

    1 shared publication
  • Michelle David

    Group MES (Métabolisme Energétique des Streptomyces), Institut de Biologie Intégrative de la Cellule (I2BC, UMR 9198), Commissariat à l’Energie Atomique et aux Energies Alternatives (CEA, CNRS), Université Paris-Saclay, 1 Avenue de la Terrasse, 91190 Gif-sur-Yvette, France

    1 shared publication
  • Renato Bensasson

    Molécules de Communication et Adaptation des Microorganismes (MCAM), Dept RDDM, UMR 7245 CNRS-MNHN, Muséum National d’Histoire Naturelle, CP54, 75005 Paris, France

    1 shared publication

Latest Publications

  • Open Access

    Nitroflavone Derivatives Inhibit the Production of Actinorhodin in Streptomyces coelicolor

    by Sana Slimene, Michelle David, Daniel Dauzonne, Renato Bensasson, Marie-Joelle Virolle, Fathi Moussa

    Streptomyces coelicolor M145 (SC) is a model strain characterised by its highly active oxidative metabolism. This results in high levels of oxidative stress and the production of actinorhodin (ACT), a blue polyketide pigment with antioxidant properties. To determine whether oxidative stress triggers ACT biosynthesis in SC, we assessed the effect of adding five nitro-flavone (NF) derivatives to the growth medium. As NF molecules are well-known antioxidants, we hypothesized that their presence in the medium would moderate ACT production. The antioxidant efficiency of NF derivatives depends on their ability to donate electrons. This ability is linked to the nature of their 4’-substituent. The Quantitative Structure–Activity Relationship (QSAR) approach and Hammett constants predict the following order: OH > OCH3 > F > H > NO2. The results obtained demonstrate a clear dose–response relationship between the reduction in ACT production by SC and the antioxidant efficiency of these molecules. Therefore, these results strongly suggest that oxidative stress plays a pivotal role in initiating ACT biosynthesis. Furthermore, these results suggest that the direct spectrophotometric assay of ACT production by SC is a rapid, reliable, and inexpensive method of evaluating the in vivo antioxidant activity of any molecule, as predicted by the QSAR approach.


  • Open Access

    Implementation of Natural Products and Derivatives in Acute Myeloid Leukemia Management: Current Treatments, Clinical Trials and Future Directions

    by Faten Merhi, Daniel Dauzonne, Brigitte Bauvois

    Bioactive natural products (NPs) may play a critical role in cancer progression by targeting nucleic acids and a wide array of proteins, including enzymes. Furthermore, a large number of derivatives (NPDs), including semi-synthetic products and pharmacophores from NPs, have been developed to enhance the solubility and stability of NPs. Acute myeloid leukemia (AML) is a poor-prognosis hematologic malignancy characterized by the clonal accumulation in the blood and bone marrow of myeloid progenitors with high proliferative capacity, survival and propagation abilities. A number of potential pathways and targets have been identified for development in AML, and include, but are not limited to, Fms-like tyrosine kinase 3 (FLT3) and isocitrate dehydrogenases resulting from genetic mutations, BCL2 family members, various signaling kinases and histone deacetylases, as well as tumor-associated antigens (such as CD13, CD33, P-gp). By targeting nucleic acids, FLT3 or CD33, several FDA-approved NPs and NPDs (i.e., cytarabine, anthracyclines, midostaurin, melphalan and calicheamicin linked to anti-CD33) are the major agents of upfront treatment of AML. However, the effective treatment of the disease remains challenging, in part due to the heterogeneity of the disease but also to the involvement of the bone marrow microenvironment and the immune system in favoring leukemic stem cell persistence. This review summarizes the current state of the art, and provides a summary of selected NPs/NPDs which are either entering or have been investigated in preclinical and clinical trials, alone or in combination with current chemotherapy. With multifaceted actions, these biomolecules may target all hallmarks of AML, including multidrug resistance and deregulated metabolism.